EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids

Yang Liu iD, Liye Tao, Zefeng Shen, Junhao Zheng, Yali Wang, Meijie Chen, Yangyang Xie, Hongjun Chen, Jingwei Cai, Haoyu Pan, Shihao Li, Renan Jin and 2 more

Cancer Medicine · 2026

DOI: 10.1002/cam4.71445 ↗

At a glance

Journal article in Cancer Medicine, 2026. Written by Yang Liu and 13 co-authors. Institution: Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School …. Major MEDLINE topics: Carcinoma, Hepatocellular, RNA, Long Noncoding, Liver Neoplasms, Biomarkers, Tumor. 68 references. The full text is freely available (open access, CC BY 4.0). Funded by: The National Natural Science Foundation of China, The Key Project in the Agricultural and Social Development Sector of the Science and Technology Bureau of Hangzhou, The Zhejiang Provincial Department of Science and Technology.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Mitochondrial permeability transition (MPT)‐driven necrosis, a recently identified form of programmed cell death, significantly influences tumor progression, therapy response, and prognosis. However, research on mitochondrial permeability transition‐driven necrosis‐related long non‐coding ribonucleic acids (MPTDNRlncRNAs) in hepatocellular carcinoma (HCC) remains limited.

Methods

In the current study, we aimed to construct an MPTDNRlncRNA signature to predict survival and classify patients with HCC. RNA sequencing and clinical data were sourced from the Cancer Genome Atlas database, while MPT‐driven necrosis‐linked genes were obtained from the Gene Set Enrichment Analysis database. We identified MPTDNRlncRNAs in HCC tumor tissues and deployed the least absolute shrinkage and selection operator‐Cox analysis to construct a predictive lncRNA signature. Immune cell infiltration variations were analyzed between high‐ and low‐risk subgroups. The MPTDNRlncRNA signature performance was estimated using statistical methodologies, and bioinformatics methods were utilized to investigate functional and pathway differences across risk groups.

Results

A seven‐lncRNA signature specific to HCC was developed, and its predictive accuracy was systematically evaluated using survival analysis, time‐dependent receiver operating characteristic curves, and Cox regression analyses. Correlation analysis demonstrated a strong association between the lncRNA signature and immune cell infiltration, several immune checkpoint targets, and its significant prognostic value for patients with HCC. Additionally, LINC02313 was recognized as a hub lncRNA in vitro, demonstrating its role in promoting cell proliferation and tumor metastasis. Finally, we validated the function of LINC02313 using a liver cancer organoid model.

Conclusion

The effective construction of an MPT‐driven necrosis‐related prognostic model highlights its potential to independently predict the prognosis of patients with HCC. These findings not only deepen our understanding of MPT‐driven necrosis but also offer novel theoretical foundations for developing more effective treatment strategies. The gene LINC02313 has been identified as a promoter of HCC's ability to proliferate and invade, underscoring its potential as a therapeutic target for HCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularRNA, Long NoncodingLiver NeoplasmsBiomarkers, TumorHumansPrognosisNecrosisOrganoidsGene Expression Regulation, NeoplasticFemaleMaleMiddle AgedGene Expression Profiling

Author keywords

HCCMPT‐driven necrosislncRNAsorganoidprognostic signature

Substances

RNA, Long NoncodingBiomarkers, Tumor

Authors and institutions

  • Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hang…
  • Zhejiang University Cancer Center, Hangzhou, China.
  • Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Hangzhou Medical College, Hangzhou, China.

ORCID profiles: Yang Liu, Xiao Liang

Funding

  • The National Natural Science Foundation of China
  • The Key Project in the Agricultural and Social Development Sector of the Science and Technology Bureau of Hangzhou
  • The Zhejiang Provincial Department of Science and Technology
  • The Major project of Health Science and Technology Program of Zhejiang Province
  • National Natural Science Foundation of China
  • Science and Technology Department of Zhejiang Province

Cite

APA

Liu, Y., Tao, L., Shen, Z., Zheng, J., Wang, Y., Chen, M., Xie, Y., Chen, H., Cai, J., Pan, H., Li, S., Jin, R., Xu, J., & Liang, X. (2026). A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids. Cancer Medicine. https://doi.org/10.1002/cam4.71445

Vancouver

Liu Y, Tao L, Shen Z, Zheng J, Wang Y, Chen M, et al. A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids. Cancer Medicine. 2026. doi:10.1002/cam4.71445

BibTeX
@article{Liu2026,
  author = {Liu, Yang and Tao, Liye and Shen, Zefeng and Zheng, Junhao and Wang, Yali and Chen, Meijie and Xie, Yangyang and Chen, Hongjun and Cai, Jingwei and Pan, Haoyu and Li, Shihao and Jin, Renan and Xu, Junjie and Liang, Xiao},
  title = {A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71445}
}
Start for free →